Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 54, 2019 - Issue 1
Submit an article Journal homepage
2,176
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Galectin 4 is a biomarker for early recurrence and death after surgical resection for pancreatic ductal adenocarcinoma

Dingyuan HuDepartment of Gastroenterology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China; ;Department of Surgery, Clinical Sciences Lund Lund University and Skåne University Hospital, Lund, Sweden; ORCID Iconhttp://orcid.org/0000-0002-7149-5501View further author information
ORCID Icon,
Daniel AnsariDepartment of Surgery, Clinical Sciences Lund Lund University and Skåne University Hospital, Lund, Sweden; ORCID Iconhttp://orcid.org/0000-0002-4357-822XView further author information
ORCID Icon,
Qimin ZhouDepartment of Surgery, Clinical Sciences Lund Lund University and Skåne University Hospital, Lund, Sweden; ORCID Iconhttp://orcid.org/0000-0002-9480-4872View further author information
ORCID Icon,
Agata SasorDepartment of Pathology, Skåne University Hospital, Lund, SwedenORCID Iconhttp://orcid.org/0000-0002-6293-463XView further author information
ORCID Icon,
Katarzyna Said HilmerssonDepartment of Surgery, Clinical Sciences Lund Lund University and Skåne University Hospital, Lund, Sweden; ORCID Iconhttp://orcid.org/0000-0002-0366-6268View further author information
ORCID Icon &
Roland AnderssonDepartment of Surgery, Clinical Sciences Lund Lund University and Skåne University Hospital, Lund, Sweden; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-0778-8630View further author information
ORCID Icon
Pages 95-100 | Received 05 Oct 2018, Accepted 16 Dec 2018, Published online: 20 Jan 2019

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
  • Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.
  • Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–361.
  • Barhli A, Cros J, Bartholin L, et al. Prognostic stratification of resected pancreatic ductal adenocarcinoma: past, present, and future. Dig Liver Dis. 2018;50:979–990.
  • Cao ZQ, Guo XL. The role of galectin-4 in physiology and diseases. Protein Cell. 2016;7:314–324.
  • Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29–41.
  • Orozco CA, Martinez-Bosch N, Guerrero PE, et al. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci USA. 2018;115:E3769–E3E78.
  • Seguin L, Camargo MF, Wettersten HI, et al. Galectin-3, a druggable vulnerability for KRAS-addicted cancers. Cancer Discov. 2017;7:1464–1479.
  • Zhao W, Ajani JA, Sushovan G, et al. Galectin-3 mediates tumor cell-stroma interactions by activating pancreatic stellate cells to produce cytokines via integrin signaling. Gastroenterology 2018;154:1524–1537. e6.
  • Hu D, Ansari D, Pawlowski K, et al. Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma. Oncotarget 2018;9:9789–9807.
  • McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387–391.
  • Hayashi T, Saito T, Fujimura T, et al. Galectin-4, a novel predictor for lymph node metastasis in lung adenocarcinoma. PLoS One. 2013;8:e81883.
  • Belo AI, van der Sar AM, Tefsen B, et al. Galectin-4 reduces migration and metastasis formation of pancreatic cancer cells. PLoS One. 2013;8:e65957.
  • Maftouh M, Belo AI, Avan A, et al. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/beta-catenin signalling in pancreatic adenocarcinoma. Oncotarget 2014;5:5335–5349.
  • Zhang Y, Morris JPT, Yan W, et al. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 2013;73:4909–4922.
  • Shimamura T, Sakamoto M, Ino Y, et al. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res. 2002;8:2570–2575.
  • Chen R, Pan S, Ottenhof NA, et al. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2012;13:899–907.
  • Tang D, Zhang J, Yuan Z, et al. Pancreatic satellite cells derived galectin-1 increase the progression and less survival of pancreatic ductal adenocarcinoma. PLoS One. 2014;9:e90476.
  • Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500–503.
  • Kuhlmann L, Nadler WM, Kerner A, et al. Identification and validation of novel subtype-specific protein biomarkers in pancreatic ductal adenocarcinoma. Pancreas 2017;46:311–322.
  • van de Wetering M, Sancho E, Verweij C, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002;111:241–250.
  • Cai Z, Zeng Y, Xu B, et al. Galectin-4 serves as a prognostic biomarker for the early recurrence/metastasis of hepatocellular carcinoma. Cancer Sci. 2014;105:1510–1517.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.